Orion Presents Data on How Levosimendan Works in ALS and Disease Biomarkers
Researchers with Orion Corporation presented new data on levosimendan‘s mechanism of action, and potential biomarkers of amyotrophic lateral sclerosis (ALS) progression. The data were recently presented in four posters at the 30th International Symposium on ALS/MND, held Dec. 4–6, in Perth, Australia. Levosimendan, a small molecule that acts…